Dr. Baselga Discusses Upcoming BOLERO-3 Data
JosÃ© Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.
In addition to the data regarding everolimus in ER-positive tumor, there is also evidence demonstrating that everolimus can enhance the effect of trastuzumab in patients with HER2-positive disease.
Data from the BOLERO-3 trial will be released soon, Baselga says. He is hopeful that the data will show benefit and provide another option for patients with HER2-positive disease.